00:04 , Apr 6, 2019 |  BioCentury  |  Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
17:15 , Feb 22, 2019 |  BC Week In Review  |  Clinical News

China approves Solasia's oral mucositis product

Solasia Pharma K.K. (Tokyo:4597) said China's National Medical Products Administration approved Episil (SP-03) to relieve pain associated with oral mucositis. The company added ¥50 (31%) to ¥210 on Feb. 21. Episil is a lipid-based liquid...
00:09 , Feb 22, 2019 |  BC Extra  |  Company News

China approves Solasia's oral mucositis product

Solasia Pharma K.K. (Tokyo:4597) said China's National Medical Products Administration approved Episil (SP-03) to relieve pain associated with oral mucositis. The company added ¥50 (31%) to ¥210 on Thursday. Episil is a lipid-based liquid that...
19:13 , May 18, 2018 |  BC Week In Review  |  Company News

Meiji launches Episil in Japan

Meiji Seika Pharma Co. Ltd. (Tokyo, Japan) launched episil (SP-3) in Japan to treat pain associated with oral mucositis (OM). Meiji has rights to commercialize the drug in Japan from Solasia Pharma K.K. (Tokyo:4597), which...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
23:52 , Oct 6, 2017 |  BioCentury  |  Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
16:44 , Aug 4, 2017 |  BC Week In Review  |  Clinical News

Japan approves Solasia's Episil

Solasia Pharma K.K. (Tokyo:4597) said Japan's Ministry of Health, Labour and Welfare (MHLW) approved Episil (episil oral spray, SP-03) to manage and relieve pain due to oral lesions, including oral mucositis or stomatitis caused by...
18:18 , Jul 7, 2017 |  BC Extra  |  Company News

Japan approves Episil

Solasia Pharma K.K. (Tokyo:4597) said Japan's Ministry of Health, Labour and Welfare (MHLW) approved Episil (SP-03) to manage and relieve pain due to oral lesions, including oral mucositis or stomatitis caused by chemotherapy or radiotherapy....
00:43 , Mar 25, 2017 |  BioCentury  |  Finance

Solasia goes to market

After becoming the first Japanese biotech to go public in 18 months, Solasia Pharma K.K. (Tokyo:4597) plans to use the proceeds to prepare to launch its first products in China. Solasia raised ¥3.6 billion ($32...
07:00 , Jul 9, 2012 |  BC Week In Review  |  Company News

Camurus, Sinclair IS Pharma, Teva sales and marketing update

Sinclair returned the majority of commercialization rights in Europe for Episil oral spray to Camurus. Sinclair, which gained European commercialization rights for Episil outside of Nordic countries through its 2011 merger with IS Pharma, retains...